According to a recent LinkedIn post from Touchlight, the company plans to attend the ASGCT 2026 conference in Boston from May 11–15, where it intends to engage with developers on its cell‑free DNA technologies. The post highlights offerings such as mbDNA and Custom Circles, which are positioned as potential alternatives to traditional plasmid DNA for gene and cell therapy applications.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Touchlight is emphasizing the ability of its cell‑free DNA production platform to help developers move faster and address perceived bottlenecks associated with plasmid‑based manufacturing. For investors, this focus on enabling gene therapy and cell therapy pipelines may signal efforts to deepen relationships with biopharma partners and capture a larger share of DNA manufacturing demand as the field scales.
By promoting conference meetings and directing interested parties to learn more or request a meeting, the post indicates an active business development push targeting ASGCT attendees. If these interactions translate into new collaborations or supply agreements, Touchlight could potentially benefit from increased revenue visibility and a stronger competitive position in the DNA manufacturing segment.